United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

genesis pharmaceuticals ltd - nitrofurantoin - oral tablet - 100mg

United States - English - NLM (National Library of Medicine)

a-s medication solutions - nitrofurantoin (unii: 927ah8112l) (nitrofurantoin - unii:927ah8112l), nitrofurantoin monohydrate (unii: e1qi2cqq1i) (nitrofurantoin - unii:927ah8112l) - nitrofurantoin 25 mg - nitrofurantoin capsules (monohydrate/macrocrystals) are indicated only for the treatment of acute uncomplicated urinary tract infections (acute cystitis) caused by susceptible strains of escherichia coli or staphylococcus saprophyticus . nitrofurantoin is not indicated for the treatment of pyelonephritis or perinephric abscesses. to reduce the development of drug-resistant bacteria and maintain the effectiveness of nitrofurantoin capsules (monohydrate/macrocrystals) and other antibacterial drugs, nitrofurantoin capsules (monohydrate/macrocrystals) should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. nitrofurantoins lack the broader tissue distribution of other therapeutic agents approved for urinary tract infections. consequently, many patients who are treated with nitrofurantoin capsules (monohydrate/macrocrystals) are predisposed to persistence or reappearance of bacteriuria. (see clinical studies.) urine specimens for culture and susceptibility testing should be obtained before and after completion of therapy. if persistence or reappearance of bacteriuria occurs after treatment with nitrofurantoin capsules (monohydrate/macrocrystals), other therapeutic agents with broader tissue distribution should be selected. in considering the use of nitrofurantoin capsules (monohydrate/macrocrystals) lower eradication rates should be balanced against the increased potential for systemic toxicity and for the development of antimicrobial resistance when agents with broader tissue distribution are utilized. anuria, oliguria, or significant impairment of renal function (creatinine clearance under 60 ml per minute or clinically significant elevated serum creatinine) are contraindications. treatment of this type of patient carries an increased risk of toxicity because of impaired excretion of the drug. because of the possibility of hemolytic anemia due to immature erythrocyte enzyme systems (glutathione instability), the drug is contraindicated in pregnant patients at term (38 to 42 weeks gestation), during labor and delivery, or when the onset of labor is imminent. for the same reason, the drug is contraindicated in neonates under one month of age. nitrofurantoin capsules (monohydrate/macrocrystals) are contraindicated in patients with a previous history of cholestatic jaundice/hepatic dysfunction associated with nitrofurantoin. nitrofurantoin capsules (monohydrate/macrocrystals) are also contraindicated in those patients with known hypersensitivity to nitrofurantoin.

Malta - English - Medicines Authority

anfarm hellas s.a. 4 achaias str. & trizinias 14564 kifissia, attiki, greece - norfloxacin - film-coated tablet - norfloxacin 400 mg - antibacterials for systemic use

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

ranvet pty. limited - nitrofurazone - topical cream, ointment, paste, gel, lotion - nitrofurazone nitrofuran active 2.0 mg/g - dermatological preps. - horse | colt | donkey | endurance horse | filly | foal | gelding | high performance horses | horses at stud | mare | pacer | pol - antibiotic - anti-infective | cracks, sores, wounds (assist healing) | open wounds - antibacterial | skin lesion | abrasions | abscesses | airsacculitis | antiseptic | avian mycoplasmas | bites | blackhead | body odours | bowed tendons | broad spectrum | burns | coccidiosis | coliform complex | conjunctivitis | cowpox | cracks | crusts | cuts | dandruff | dermatological disorders | dermatosis | dry skin | dysentery | eczema | endometritis | enteric diseases | enzootic pneumonia | feed efficiency | fungal infections | girth galls | infections | inflammed pads | itching | keratolytic | lacerations | mastitis | mycoplasmas | odours | open wounds | otitis | pruritis | queensland itch | respiratory disease | saddle rash | salmonellosis | scabs | scaly skin | sheath rot | skin irritations | sores | swine dysentery | teat cracking | teat infections | topical infections | udder sores | weight gain | wire cuts | wounds

Malta - English - Medicines Authority

morningside healthcare limited unit c, harcourt way, leicester, le19 1wp, united kingdom - nitrofurantoin - hard capsule - nitrofurantoin 50 milligram(s) - antibacterials for systemic use

Malta - English - Medicines Authority

morningside healthcare (malta) ltd 93, mill street, qormi, qrm 3102 , malta - nitrofurantoin - hard capsule - nitrofurantoin 50 mg - antibacterials for systemic use

Ireland - English - HPRA (Health Products Regulatory Authority)

azure pharmaceuticals ltd - nitrofurantoin - capsule, hard - 100 milligram(s) - nitrofurantoin

Ireland - English - HPRA (Health Products Regulatory Authority)

azure pharmaceuticals ltd - nitrofurantoin - capsule, hard - 50 milligram(s) - nitrofurantoin

Australia - English - Department of Health (Therapeutic Goods Administration)

boucher & muir pty ltd - nitrofurantoin, quantity: 100 mg - capsule, hard - excipient ingredients: titanium dioxide; lactose monohydrate; iron oxide yellow; maize starch; purified talc; purified water; gelatin; sodium lauryl sulfate - treatment of urinary tract infections such as cystitis and pyelitis when due to susceptible pathogens. nitrofurantoin does not reach effective levels in plasma and consequently is not indicated for cortical or perinephric abscesses and in cases of prostatitis.

Australia - English - Department of Health (Therapeutic Goods Administration)

boucher & muir pty ltd - nitrofurantoin, quantity: 50 mg - capsule, hard - excipient ingredients: titanium dioxide; maize starch; purified talc; iron oxide yellow; lactose monohydrate; purified water; gelatin; sodium lauryl sulfate - treatment of urinary tract infections such as cystitis and pyelitis when due to susceptible pathogens. nitrofurantoin does not reach effective levels in plasma and consequently is not indicated for cortical or perinephric abscesses and in cases of prostatitis.